Drugs / Bromelain
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05687760 | Feb 2023 | — | Cairo University | Unknown | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT06505759 | Jul 2024 → Jul 2025 overdue | periodontal disorder | Krishnadevaraya College of Dental Sciences & Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06775392 | Jan → Aug 2024 | periodontal disorder | Krishnadevaraya College of Dental Sciences & Hospital | Completed | No outcome recorded |
| Phase 1 | NCT05220605 | Jul → Aug 2022 | acute respiratory distress syndrome, pneumonia | Mucpharm Pty Ltd | Completed | No outcome recorded |
| Phase 1 | NCT04982146 | Sep 2021 → May 2022 | pseudomyxoma peritonei | Maimónides Biomedical Research Institute of Córdoba | Unknown | No outcome recorded |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT06981767 | Feb → Jul 2026 overdue | lichen planus, oral | Cairo University | Recruiting | No outcome recorded |
| Phase 2 | NCT06993337 | Jun 2025 → May 2026 overdue | aphthous stomatitis | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT03976973 | May 2022 → Nov 2023 | pseudomyxoma peritonei | Mucpharm Pty Ltd | Unknown | No outcome recorded |
| Phase 2 | NCT04512482 | Jun → Jul 2018 | smooth surface dental caries | Indiana University | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT07088042 | Sep 2024 → Feb 2025 | pulpitis | Ain Shams University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06298383 | Jun 2025 → Feb 2026 | pulpitis | Cairo University | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04040660 | — | — | MediWound Ltd | Approved for marketing | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT02340845 Comparator | May 2014 → Jan 2015 | cancer | Oeyama-Moto Cancer Research Foundation | Unknown | No outcome recorded |
| Phase 3 | NCT05681312 Comparator | May → Sep 2024 | — | University of Baghdad | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-04-07 | MediWound Ltd | Results MediWound to Present New EscharEx® Data at Leading Wound Care Conferences mediwound.com ↗
Post-hoc analysis demonstrates the efficacy of bromelain-based enzymatic debridement in DFUs, supporting ongoing development in this indication. |
| 2025-12-10 | MediWound Ltd | Results MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries mediwound.com ↗
MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the peer-reviewed publication of new prospective clinical data showing that NexoBrid ® substantially reduces embedded particles associated with traumatic tattoos following abrasion and blast injuries. |
| 2025-05-13 | MediWound Ltd | Results MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers mediwound.com ↗
Compared to SANTYL, EscharEx achieved faster and more effective debridement and promoted healthier granulation tissue, both key to optimal wound bed preparation. |
| 2024-07-29 | MediWound Ltd | Results MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers mediwound.com ↗
The significant superiority of EscharEx over the current non-surgical standard of care in achieving optimal wound bed preparation could dramatically enhance healing outcomes and provide a viable alternative to surgical debridement. |
| 2024-02-12 | MediWound Ltd | Results MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study mediwound.com ↗ |
| 2022-12-19 | MediWound Ltd | Results MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma mediwound.com ↗
The data shows MW005 to be safe and well-tolerated, with patients achieving complete clinical and histological clearance of their target lesions. |
| 2022-10-18 | MediWound Ltd | Results MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022 mediwound.com ↗
The data demonstrated EscharEx to be significantly better than gel vehicle and the non-surgical standard of care across multiple measures including incidence of complete debridement, time to achieve complete debridement and granulation tissue formation. |
| 2022-04-12 | MediWound Ltd | Results MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022 mediwound.com ↗
The poster entitled: “ Results from an Ongoing Open Phase 2 Study Assessing the Safety, Efficacy and Pharmacological Effects of Bromelain-based Enzymatic Debridement on Biofilm , Microbial loads and Cytokines in patients with DFU and VLU, ” featured data from an ongoing Phase 2 study that showed EscharEx to debride wounds and promote wound area reduction, while reducing biofilm and bacterial bioburden safely and effectively. |
| 2021-06-07 | MediWound Ltd | Results MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal mediwound.com ↗
All of the BCCs were completely removed and two of the lesion’s sites were surgically excised after 6 months with no tumor cells noted on histopathology. |
All press releases naming this drug 9 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bromelain | “The API is a concentrate of proteolytic enzymes enriched in Bromelain extracted from the stem of Ananas comosus (pineapple plant)” NCT04040660 ↗13“Bromelain is a natural proteolytic enzyme derived from pineapple, recognized for its broad range of pharmacological properties.” NCT06993337 ↗ “Tibrolin is a fixed dose combination of(Trypsin 48 mg, Bromelain 90 mg) and a bioflavonoid (Rutoside 100 mg)” NCT05681312 ↗ “Received Limitless Allzyme Max® Trypsin/Chymotrypsin/Bromelain(15 microkatal/42microkatal/240 GDU)” NCT07088042 ↗ “Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei” NCT04982146 ↗ “BromAc is a product that combines two existing products (Bromelain and Acetylcysteine)” NCT05220605 ↗ |
| Known as | Comosain | “Bromelain (Comosain) extract, derived from the stem and fruit of Ananas Comosus will be administered orally each day.” NCT02340845 ↗ |
| Modality | Protein / enzyme biologic | “concentrate of proteolytic enzymes” NCT04040660 ↗ |
| Route | Oral | “administered orally” NCT02340845 ↗ |